Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Clin Infect Dis ; 73(2): e345-e354, 2021 07 15.
Article in English | MEDLINE | ID: mdl-32615591

ABSTRACT

BACKGROUND: Death in patients with chikungunya is rare and has been associated with encephalitis, hemorrhage, and septic shock. We describe clinical, histologic, and immunohistochemical findings in individuals who died following chikungunya virus (CHIKV) infection. METHODS: We identified individuals who died in Puerto Rico during 2014 following an acute illness and had CHIKV RNA detected by reverse transcriptase-polymerase chain reaction in a pre- or postmortem blood or tissue specimen. We performed histopathology and immunohistochemistry (IHC) for CHIKV antigen on tissue specimens and collected medical data via record review and family interviews. RESULTS: Thirty CHIKV-infected fatal cases were identified (0.8/100 000 population). The median age was 61 years (range: 6 days-86 years), and 19 (63%) were male. Death occurred a median of 4 days (range: 1-29) after illness onset. Nearly all (93%) had at least 1 comorbidity, most frequently hypertension, diabetes, or obesity. Nine had severe comorbidities (eg, chronic heart or kidney disease, sickle cell anemia) or coinfection (eg, leptospirosis). Among 24 fatal cases with tissue specimens, 11 (46%) were positive by IHC. CHIKV antigen was most frequently detected in mesenchymal tissues and mononuclear cells including tissue macrophages, blood mononuclear cells, splenic follicular dendritic cells, and Kupffer cells. Common histopathologic findings were intra-alveolar hemorrhage and edema in the lung, chronic or acute tenosynovitis, and increased immunoblasts in the spleen. CHIKV infection likely caused fatal septic shock in 2 patients. CONCLUSIONS: Evaluation of tissue specimens provided insights into the pathogenesis of CHIKV, which may rarely result in septic shock and other severe manifestations.


Subject(s)
Chikungunya Fever , Chikungunya virus , Diabetes Mellitus , Chikungunya Fever/complications , Chikungunya Fever/epidemiology , Comorbidity , Humans , Male , Middle Aged , Puerto Rico
2.
Emerg Infect Dis ; 24(1): 114-117, 2018 01.
Article in English | MEDLINE | ID: mdl-29261094

ABSTRACT

Postmortem examination results of a patient with Guillain-Barré syndrome and confirmed Zika virus infection revealed demyelination of the sciatic and cranial IV nerves, providing evidence of the acute demyelinating inflammatory polyneuropathy Guillain-Barré syndrome variant. Lack of evidence of Zika virus in nervous tissue suggests that pathophysiology was antibody mediated without neurotropism.


Subject(s)
Autopsy , Coinfection/virology , Guillain-Barre Syndrome/complications , Zika Virus Infection/complications , Aged , Coinfection/pathology , Guillain-Barre Syndrome/pathology , Guillain-Barre Syndrome/virology , Humans , Male , Puerto Rico , Zika Virus Infection/pathology , Zika Virus Infection/virology
3.
Am J Trop Med Hyg ; 91(4): 760-5, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25092820

ABSTRACT

Co-infection with pathogens that cause acute febrile illness creates a diagnostic challenge as a result of overlapping clinical manifestations. Here, we describe four fatal cases of Leptospira species/dengue virus co-infection in Puerto Rico. Although all patients sought care early, antibiotic administration was delayed for most. Steroids were administered to all patients, in most cases before antibiotics. These cases show the need for clinicians evaluating patients in or recently returned from the tropics with acute febrile illness to consider both dengue and leptospirosis. Furthermore, they illustrate the need for nucleic acid- or antigen-based rapid diagnostic tests to enable timely patient diagnosis and management. In particular, antibiotic therapy should be initiated early for patients with suspected leptospirosis, and steroids should not be administered to patients with suspected dengue.


Subject(s)
Dengue Virus/isolation & purification , Dengue/diagnosis , Leptospira/isolation & purification , Leptospirosis/diagnosis , Adult , Aged , Anti-Bacterial Agents/administration & dosage , Coinfection , Dengue/drug therapy , Dengue/virology , Fatal Outcome , Humans , Leptospirosis/drug therapy , Leptospirosis/microbiology , Male , Middle Aged , Puerto Rico , Steroids/administration & dosage , Young Adult
4.
Viral Immunol ; 25(2): 141-52, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22486305

ABSTRACT

Human papillomavirus (HPV) is associated with premalignant lesions such as high-grade cervical intraepithelial neoplasia (CIN-III) with potential progression to cervical carcinoma. There are now preventive vaccines against HPV. However, no effective therapeutic vaccine or immunological treatment exists for individuals already infected or for the 470,000 women that develop high-grade dysplasia, carcinoma in situ, and cervical cancer each year. More than half of these women die from cervical cancer. Relative non-immunogenicity of HPV infection is one of the main reasons for the difficulty in designing a comprehensive therapeutic vaccine against HPV-induced premalignant lesions and cervical carcinoma. HPV E6 and E7 proteins, the major HPV oncogenes, are highly immunogenic but fail to induce cross-reactive and protective immune responses against heterologous strains. We designed and synthesized a therapeutic peptide vaccine comprised of multivalent peptide mixtures called hypervariable epitope constructs (HECs) that represent the major epitope variants of the oncogenic E7 structural protein, and assessed their immunogenicity and in vivo efficacy in mice. Our results show that this peptide vaccine can induce strong, HPV-specific, T-helper cell and CTL responses. More significantly, we have demonstrated that the vaccine is efficacious as a therapeutic agent in a mouse HPV tumor model. Therefore, the HPV HEC vaccine approach described herein can potentially prevent progression of HPV-associated premalignant lesions, and may also be therapeutic against tumors associated with HPV.


Subject(s)
Carcinoma/therapy , Immunotherapy/methods , Papillomaviridae/immunology , Papillomavirus E7 Proteins/immunology , Papillomavirus Infections/therapy , Papillomavirus Vaccines/immunology , Uterine Cervical Neoplasms/therapy , Animals , Antigens, Viral/administration & dosage , Antigens, Viral/immunology , Disease Models, Animal , Epitopes/immunology , Female , Mice , Mice, Inbred C57BL , Papillomavirus E7 Proteins/administration & dosage , Papillomavirus Infections/complications , Papillomavirus Vaccines/administration & dosage , T-Lymphocytes/immunology , Treatment Outcome , Vaccines, Subunit/administration & dosage , Vaccines, Subunit/immunology
5.
J Immunol ; 180(4): 2174-86, 2008 Feb 15.
Article in English | MEDLINE | ID: mdl-18250424

ABSTRACT

One of the major obstacles in the design of an effective vaccine against HIV-1 is its antigenic variation, which results in viral escape from the immune system. Through a bioinformatics approach, we developed an innovative multivalent HIV-1 vaccine comprised of a pool of 176 lipidated and nonlipidated peptides representing variable regions of Env and Gag proteins. The potency and breadth of the candidate vaccine against a panel of HIV-1 subtypes was evaluated in nonhuman primate (cynomolgus macaques) and humanized mouse (HLA-A2.1) models. The results demonstrate strong immunogenicity with both breadth (humoral and cellular immunity) and depth (immune recognition of widely divergent viral sequences) against heterologous HIV-1 subtypes A-F.


Subject(s)
AIDS Vaccines/immunology , Epitopes/immunology , HIV Antibodies/biosynthesis , HIV-1/classification , HIV-1/immunology , Vaccines, Subunit/immunology , AIDS Vaccines/administration & dosage , AIDS Vaccines/chemical synthesis , Amino Acid Sequence , Animals , CD4-Positive T-Lymphocytes/cytology , CD4-Positive T-Lymphocytes/immunology , Cell Proliferation , Cytotoxicity, Immunologic , Gene Products, gag/administration & dosage , Gene Products, gag/immunology , HIV Envelope Protein gp120/administration & dosage , HIV Envelope Protein gp120/immunology , Lipid Metabolism/immunology , Macaca fascicularis , Mice , Mice, Transgenic , Molecular Sequence Data , Vaccines, Attenuated/administration & dosage , Vaccines, Attenuated/chemical synthesis , Vaccines, Attenuated/immunology , Vaccines, Subunit/administration & dosage , Vaccines, Subunit/chemical synthesis
6.
P R Health Sci J ; 25(1): 67-9, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16883680

ABSTRACT

Post-mortem medical examiner samples may be useful for sentinel surveillance of disorders usually detected by antibody determinations on specimens from ill patients or from surveys. We found anti-dengue IgM positivity in 3% (23/780) and anti-dengue IgG positivity in 77% (597/777) of sera obtained at the Puerto Rico medical examiner (Institute of Forensic Sciences) in December 2000, April 2001, and October 2001. This approach may be a useful alternative for estimating the population prevalence of serologic markers for dengue and other infectious diseases.


Subject(s)
Cadaver , Dengue/blood , Dengue/epidemiology , Immunoglobulin G/blood , Immunoglobulin M/blood , Population Surveillance/methods , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Dengue/diagnosis , Dengue/immunology , Female , Humans , Infant , Infant, Newborn , Male , Middle Aged , Puerto Rico
7.
Viral Immunol ; 18(4): 689-94, 2005.
Article in English | MEDLINE | ID: mdl-16359235

ABSTRACT

Using simian immunodeficiency virus (SIV) infection of rhesus macaques to model human immunodeficiency virus (HIV) infection of humans, we assessed whether broadly reactive vaccine-induced humoral immunity would remain broadly reactive after viral challenge, and whether there would be significant differences in anamnestic antibody responses if animals were challenged when predominately effector or memory lymphocyte populations were present. Animals immunized over a prolonged period and challenged 11 months after vaccination mounted more broadly reactive and stronger humoral immunity than those rapidly vaccinated and challenged 2 weeks after their final vaccinations. These data suggest that vaccination schedule and the timing of virus challenge should be considered when evaluating future candidate HIV vaccines.


Subject(s)
Antibodies, Viral/blood , Immunologic Memory , SAIDS Vaccines/immunology , Simian Acquired Immunodeficiency Syndrome/prevention & control , Simian Immunodeficiency Virus/immunology , AIDS Vaccines/administration & dosage , AIDS Vaccines/immunology , Animals , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , HIV Antibodies/blood , HIV-2/immunology , Immunization Schedule , Macaca mulatta , Male , Neutralization Tests , SAIDS Vaccines/administration & dosage , Simian Acquired Immunodeficiency Syndrome/immunology , Simian Acquired Immunodeficiency Syndrome/virology , Simian Immunodeficiency Virus/physiology , Time Factors , Vaccination , Viral Envelope Proteins/immunology , Viral Load
8.
Viral Immunol ; 17(3): 436-9, 2004.
Article in English | MEDLINE | ID: mdl-15357909

ABSTRACT

Human immunodeficiency virus type 2 (HIV-2) evolved from the zoonotic transmission of simian immunodeficiency virus (SIV) that naturally infects sooty mangabeys found in West Africa. Using sera from HIV-2-infected humans, we discovered that an hypervariable region (the V4 loop) of HIV-2 induces antibody responses only weakly reactive against itself but strongly reactive against analogous sequences from the V4 loop of strains of SIV. Available sequence data indicates that all strains of HIV-2 have large deletions in the V4 region that truncate an immunodominant neutralizing B cell epitope among strains of SIV. Infection of a macaque with a sequenced clone of HIV-2 similarly elicited antibodies that poorly recognized the V4 loop of HIV-2 but readily bound to analogous SIV sequences. Our data are consistent with a scenario whereby a disparate antibody response directed against the V4 loop may have influenced the selective expansion and survival of HIV-2 in humans.


Subject(s)
HIV Antibodies/biosynthesis , HIV-2/immunology , Simian Immunodeficiency Virus/immunology , Biological Evolution , Epitopes, B-Lymphocyte , Humans , Immunodominant Epitopes
9.
Immunology ; 112(2): 321-7, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15147575

ABSTRACT

An ideal prophylactic vaccine against human papillomaviruses (HPV) would be one that can induce broadly reactive antibody titres to at least the major oncogenic strains of HPV. It has been previously shown that HPV structural proteins are highly immunogenic but fail to elicit cross-reactive immune responses against heterologous strains of HPV. Recent studies have demonstrated that the immunity induced by virus-like particles is mostly type specific. In the present study, we determined the breadth of reactivity of antibodies induced in mice immunized with hypervariable epitope constructs (HECs), which represent sequence variants of immunodominant B-cell epitopes of the major capsid protein L1 of HPV. In order to test the breadth of reactivity, sera from immunized mice were tested against peptides representing analogous sequences of HPV types 16, 18, 31 and 45. Mice immunized with HECs based on two epitopes mounted antibody responses that cross-reacted with two different analogues, 16 and 18. Significantly, antibodies from mice immunized with HECs also inhibited haemagglutination mediated by HPV-16 L1 VLPs, suggesting that immunization resulted in the development of antibodies that could bind to viral capsid proteins in their native conformation. Our observations suggest that HECs may overcome the restriction of type specific immunity against HPV.


Subject(s)
Antibodies, Viral/biosynthesis , Capsid Proteins , Complementarity Determining Regions/immunology , Epitopes, B-Lymphocyte/immunology , Papillomaviridae/immunology , Animals , Antibodies, Viral/immunology , Antibody Specificity , Antigens, Viral/immunology , Cross Reactions/immunology , Erythrocytes/immunology , Female , Hemagglutination/immunology , Humans , Immunization/methods , Mice , Oncogene Proteins, Viral/immunology , Papillomaviridae/classification , Peptide Fragments/immunology , Viral Vaccines/immunology
10.
Clin Immunol ; 111(1): 22-7, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15093548

ABSTRACT

Cellular immunity against multiple Hepatitis C virus (HCV) proteins is observed in patients acutely infected with HCV most of whom later resolve infection. We wished to assess humoral immunity in patients infected with HCV 1a or 1b genotypes in relation to viral load using plasma samples from HCV-infected individuals and a panel of peptides representing immunodominant epitopes of HCV structural and nonstructural proteins. Plasma from HCV 1a- and 1b-infected patients, respectively, were divided into two groups: patients with low viral load (<==100,000 RNA copies/ml) and patients with high viral load (>/=10,000,000 RNA copies/ml). The antigens were peptides representing epitopes from immunodominant regions of HCV core, E2, NS3, and NS4 proteins, as well as the hypervariable (HVR) epitopes in E2 from genotypes 1a and 1b. Individuals infected with HCV 1a evoked a stronger immune response to many immunodominant epitopes of HCV relative to individuals infected with HCV 1b. Moreover, among individuals infected with HCV 1a, those with low viral loads mounted significantly greater responses against these epitopes than did individuals with high viral loads. Our observations demonstrate that quantitatively different antibody responses are elicited against HCV depending on the genotype of infecting virus, and suggest that humoral immunity directed against multiple immunodominant epitopes in HCV 1a-infected individuals may help lower viral load in vivo.


Subject(s)
Antibody Formation , Hepacivirus/immunology , Hepatitis C Antibodies/immunology , Immunodominant Epitopes , Enzyme-Linked Immunosorbent Assay , Genotype , Hepacivirus/genetics , Humans , Peptides/immunology , Viral Core Proteins/immunology , Viral Load
11.
J Eukaryot Microbiol ; 50(1): 43-8, 2003.
Article in English | MEDLINE | ID: mdl-12674478

ABSTRACT

Sexually transmitted diseases (STDs) caused by bacteria and protozoa play an important role in the epidemiology of human immunodeficiency virus (HIV-1) infection. Human trichomoniasis, produced by the protozoan parasite Trichomonas vaginalis, is one of the most common STDs, and is a cause of mucosal lesions in the urogenital tract, which may increase the risk for HIV infection. However, there are no reports concerning the outcome of in vitro interactions between HIV particles and trichomonads. Therefore, we incubated T. vaginalis with three subtypes of HIV-1 (A, B, and D), as well as with HIV-1-infected lymphocytes, and analyzed the interactions with immunofluorescence microscopy and transmission electron microscopy. Our results demonstrated that HIV-1 particles attach and are incorporated into T. vaginalis through endocytic vesicles and are degraded within cytoplasmic vacuoles in approximately 48 h. There was no ultrastructural evidence of HIV-1 replication in trichomonads. These results demonstrated that trichomonads may internalize and harbor HIV-1 particles for short periods of time. In addition, under in vitro conditions, T. vaginalis ingests and digests HIV-1-infected lymphocytes.


Subject(s)
Cell Adhesion , HIV-1/pathogenicity , Lymphocytes/virology , Trichomonas vaginalis/virology , Animals , Cells, Cultured , Female , HIV-1/genetics , HIV-1/growth & development , Humans , Lymphocytes/physiology , Time Factors , Trichomonas vaginalis/growth & development , Trichomonas vaginalis/ultrastructure , Tumor Cells, Cultured , Vacuoles/virology , Virion/ultrastructure
12.
FEBS Lett ; 519(1-3): 173-7, 2002 May 22.
Article in English | MEDLINE | ID: mdl-12023039

ABSTRACT

Methadone, a regimen for the treatment of opioid dependency, was found to induce the expression of CCR5, a co-receptor for human immunodeficiency virus (HIV)/simian form of HIV (SIV) entry, on human CEM x174 lymphocytes. Both CCR5 mRNA and protein were elevated in methadone-treated cells. A concomitant increase of mu opioid receptors was also observed. Upon methadone exposure, SIVmac239-infected CEM x174 cells released greater amounts of virus particles as revealed by both the number of syncytia formation and reverse transcriptase activities. Similar methadone effect was not observed on CEM x174 cells infected with other simian retroviruses that do not depend on CCR5 for cellular entry. These studies raise concerns considering methadone as an innocuous morphine substitute.


Subject(s)
Lymphocytes/drug effects , Lymphocytes/virology , Methadone/pharmacology , Narcotics/pharmacology , Receptors, CCR5/metabolism , Simian Immunodeficiency Virus , Cell Line , Enzyme Activation/drug effects , Gene Expression/drug effects , Giant Cells/drug effects , Giant Cells/pathology , Humans , Lymphocytes/metabolism , Naloxone/pharmacology , Narcotic Antagonists/pharmacology , RNA, Messenger/metabolism , RNA-Directed DNA Polymerase/biosynthesis , Receptors, CCR5/genetics , Receptors, Opioid, mu/genetics , Receptors, Opioid, mu/metabolism , Retroviridae Infections/metabolism , Retroviridae Infections/virology , Retroviruses, Simian/growth & development , Simian Immunodeficiency Virus/growth & development , Virus Replication/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...